The Department of Science and Technology-Food and Nutrition Research Institute (DOST-FNRI) is formulating an enhanced nutribun (E-Nutribun) in response to the need for healthier bread.
DOST Secretary Fortunato dela Peña said four different formulations were tested with varying quantity of ingredients. The first reformulated E-Nutribun consisted of bread flour, squash puree, sugar, skim milk, shortening, salt, bread improver and yeast.
Dela Peña said the E-Nutribun would be for the implementation of the government’s Supplementary Feeding Program during community quarantine or other similar emergencies.
The E-Nutribun is set to be launched during Nutrition Month before the end of July. AAC
MANILA, Philippines – The Department of Science and Technology (DOST) on Tuesday announced that 13 hospitals will be involved in the solidarity trials of the World Health Organization (WHO) for potential novel coronavirus disease (COVID-19) vaccines in the country.
In a statement, DOST Secretary Fortunato dela Peña said the Inter-Agency Task Force for the Management of Emerging Infectious Disease (IATF-MEID) has adopted the agency’s recommendation for zoning on the solidarity trials for the vaccine candidates against COVID-19 which will be conducted this year.
Dela Peña said the vaccine candidates will be tested in eight trial zones, involving a total of 13 hospitals.
He identified these facilities as the Philippine General Hospital, Manila Doctors Hospital, San Lazaro Hospital, Lung Center of the Philippines, St. Luke’s Medical Center-Quezon City, the Research Institute for Tropical Medicine, Makati Medical Center, The Medical City, and St. Luke’s Medical Center-BGC, Vicente Sotto Memorial Medical Center, Chong Hua Hospital in Cebu City, De La Salle Health Sciences Institute in Cavite, and Southern Philippines Medical Center in Davao City.
The WHO solidarity trials will start this October and expected to be completed by the second quarter of the following year.
The DOST chief also confirmed that the Philippines is in agreement with five COVID- 19 vaccine developers that will enable clinical trial data sharing.
MANILA, Philippines – Nagsimula na ang recruitment ng volunteer para sa gagawing clinical trials sa lagundi bilang supplemental treatment sa mga indibidwal na nahawa ng novel coronavirus disease (COVID-19), ayon sa Department of Science and Technology (DOST).
Sa panayam sa programang Get It Straight with Daniel Razon ngayong Miyerkules, Sinabi ni DOST Secretary Fortunato dela Peña na 200 volunteer ang kakailangan sa clinical trials.
Aabot sa P4 milyong pondo ang inilaan para sa gagawing pagsusuri.
Ayon kay Dela Peña, layon ng clinical trials na alamin kung mabisang supplemental treatment ang lagundi sa sintomas ng COVID-19 at kung makatutulong ito upang hindi lumala ang kondisyon ng mga taong may mild case ng coronavirus infection.
Gagawin ang trial sa Quezon Institute Quarantine Center, Santa Ana Hospital at PNP-NCR Community Quarantine Center. Pangungunahan ito ng mga tauhan ng Philippine General Hospital.
Inihayag rin ng kalihim ng DOST na nagpapatuloy na ang clinical trials para naman sa virgin coconut oil (VCO) na sinasabing nagtataglay ng anti-viral property na maaaring pangontra sa COVID-19.
Ani Dela Peña, nasa 40 volunteers ang kasalukuyang sumasailalim sa VCO trials at kailangan pa nila ng dagdag na 16 upang makumpleto ang 65 na kailangan para sa pagsusuri.
Batay sa isinagawa nilang in-vitro trial, lumalabas na nakatutulong ang VCO para bahagyang mapababa ang infectivity ng SARS-COV2, ang virus na sanhi ng COVID-19.
Sa pagtaya ng opisyal, maaaring magkaroon ng resulta ang trials sa loob ng dalawang buwan.
“I-eextend na lang namin yung trials sa Valenzuela Emergency Medical Center nang sa ganoon, mas dumami pa yung ating volunteers na pagbabasehan. So humigit kumulang siguro baka within two months ay magkakaroon na tayo ng magandang analysis tungkol dito sa VCO,” ang sabi ni Dela Peña.
Maliban sa lagundi, pinag-aaralan na rin ng DOST ang pagsasagawa ng pagsusuri sa halamang tinatawag na tawa-tawa bilang supplemental treatment sa COVID-19 ngunit hinihintay pa nila ang pahintulot ng Food and Drug Administration para sa pagsisimula ng clinical trial.
“Lahat naman ng ating mga natural products na ginagamit clinical trials at nagdaan muna sa toxicity at harmful effects testing,” ani Dela Peña. – RRD (mula sa ulat ni Correspondent Vincent Arboleda)
MANILA, Philippines — Anti-cough herb, Lagundi, may soon be tested as a possible therapeutic supplement in the treatment of patients with coronavirus disease (COVID-19).
The trial of the medicinal herb, known scientifically as vitex negundo, may start next month according to Science and Technology Secretary Fortunato dela Peña.
He added that the University of the Philippines-Manila Ethics Board has already issued clearance for such work and experts are just waiting for the approval of the Food and Drug Administration (FDA).
The project is expected to run for five months, after which the output of the project will be given to COVID-19 patients.
Dela Peña explained that Lagundi is registered with the FDA as a therapeutic medicine for cough and respiratory infections.
It has anti-viral properties and can be used as an anti-inflammatory and antipyretic.
“Siya [lagundi] ay ibibigay para ang pasyente ay magkaroon ng (it will be given to patients to provide) relief from the symptoms,” Secretary Dela Peña said.
“Kasi ang usual symptoms naman ng COVID-19 includes iyong sore throat, iyong fever, iyong ubo, at iyan ay ina-address ng lagundi. Kaya titingnan kung ano ang magiging epekto kung sila ay bibigyan niyan,” he added.
(The usual symptoms of COVID-19 include sore throat, fever and cough. These are the conditions that lagundi addresses. So we will look at the effects of lagundi on the patients.)
The Secretary also revealed that another part of their lineup for clinical trials is the tawa-tawa plant.
Meanwhile, the clinical trial on virgin coconut oil still continues and Dela Peña noted some positive results of VCO in COVID-19 patients taking it.
“Doon sa mga binigyan kasi mga mild cases iyon, marami nang nakauwi doon sa mga confined,” he said.
(It was given to mild cases. Many of those who were confined had already gone home.)
“Pero ang protocol dyan ay tatapusin ang pagbibigay ng VCO for 28 days kahit nakauwi na para ma-compare yung kanyang status at day zero, at day 14 and at day 28,” he concluded.
(But the protocol is to complete the intake of VCO for 28 days even after returning home in order to have a comparison of the patients’ condition from day zero, at day 14 and at day 28.) MNP (with reports from Rey Pelayo)
UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.